Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Regeneron does not undertake any obligation ... For my remarks today, I will review some of our key performance drivers, then briefly discuss a few of our more differentiated pipeline ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

Some companies have announced diversity rollbacks — but many more are deleting or softening language from their investor ...

Regeneron and Alnylam are to research treatments ... Alnylam filed its first RNAi therapy with the FDA last month, asking the regulator to review patisiran for the rare disease Hereditary ATTR ...

AZ and Regeneron will collaborate on finding small ... using an acquired priority voucher to speed up the review time. Looming on the horizon is Lilly's tirzepatide, which has posted impressive ...

29 August 2024 Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the ...

The stock's fall snapped a three-day winning streak.

Regeneron Pharmaceuticals is stepping up its shareholder returns with the launch of a quarterly dividend and a $3 billion increase to its stock-buyback program. Regeneron on Tuesday said its board ...

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic ...